Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct;29(5):379-384.
doi: 10.21147/j.issn.1000-9604.2017.05.01.

Secretory carcinoma - impact of translocation and gene fusions on salivary gland tumor

Ryoko Inaki  1 , Masanobu Abe  1   2 , Liang Zong  1   2 , Takahiro Abe  1 , Aya Shinozaki-Ushiku  1 , Tetsuo Ushiku  1 , Kazuto Hoshi  1
Affiliations

Secretory carcinoma - impact of translocation and gene fusions on salivary gland tumor

Ryoko Inaki et al. Chin J Cancer Res. 2017 Oct.

Abstract

Secretory carcinoma (SC), previously described as mammary analogue secretory carcinoma (MASC), is a recently described salivary gland tumor which morphologically resembles mammary secretory carcinoma. The first description of SC/MASC, reported by Skálová et al. in 2010, was as a rare salivary carcinoma imitating secretory carcinoma of the breast. SC/MASC is a unique salivary gland tumor with morphological overlap with acinic cell carcinoma (AciCC), mucoepidermoid carcinoma (MEC), and adenocarcinoma not otherwise specified (ADC-NOS). SC/MASC shares similar clinicopathological features with AciCC. As a critical difference between SC/MASC and AciCC, SC/MASC characteristically has the chromosomal translocation t(12;15)(p13;q25) which leads to a fusion gene between the ETV6 gene on chromosome 12 and the NTRK3 gene on chromosome 15. This genetic background is an important differential diagnostic finding for excluding other salivary gland tumors and may be a critical factor determining the prognosis for patients with SC/MASC. Research in recent years has provided a large body of new data on SC/MASC and suggests the possibility that the ETV6-NTRK3 translocation could be a therapeutic target. Here, we review the morphological and clinicopathological features of SC/MASC and discuss new directions for therapy.

Keywords: ETV6-NTRK3 fusion gene; MASC; Secretory carcinoma; mammary analogue secretory carcinoma; salivary gland tumor.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ozguroglu M, Tascilar K, Ilvan S, et al. Secretory carcinoma of the breast. Case report and review of the literature. Oncology. 2005;68:263–8. doi: 10.1159/000086782. - DOI - PubMed
    1. Thompson L. World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Ear Nose Throat J. 2006;85:74. - PubMed
    1. Brandt SM, Swistel AJ, Rosen PP. Secretory carcinoma in the axilla: probable origin from axillary skin appendage glands in a young girl. Am J Surg Pathol. 2009;33:950–3. doi: 10.1097/PAS.0b013e31819c2628. - DOI - PubMed
    1. Tognon C, Knezevich SR, Huntsman D, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma . Cancer Cell. 2002;2:367–76. - PubMed
    1. Laé M, Fréneaux P, Sastre-Garau X, et al. Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum. Mod Pathol. 2009;22:291–8. doi: 10.1038/modpathol.2008.184. - DOI - PubMed

LinkOut - more resources